Two major shifts are transforming the landscape of hospice. First, private equity firms are gobbling up hospices. As Melissa Aldridge,…
The science of balancing safety and independence of older drivers has come a long way. Some key points from our…
You have a patient with dementia severe enough that she cannot recognize relatives. She falls and breaks her hip. Should…
Most studies in geriatrics have used metrics such as survival time or disability in activities of daily living as their…
The FDA label for the amyloid antibody aducanumab (Aduhelm) started off exceedingly broad, basically including anyone with Alzheimer’s disease, but…
On June 7th, 2021 FDA approved the amyloid beta-directed antibody aducanumab (Aduhelm) for the Treatment of Alzheimers. This approval of…
In a new study in JAGS, Matthew Growdon found that the average number of medications people with dementia took in…
There are no currently approved disease modifying drugs for Alzheimer’s disease, but in a couple months that may change. In July…
Where are we with Alzheimers? Are we about to see a revolution in how we diagnose and treat it with Amyloid…
Surrogate decision‐making around life-sustaining treatments in the hospital even in the best of circumstances is hard. It’s maybe even harder…